Octreotide Acetate: Brands, Price & Uses in Bangladesh

Octreotide Acetate is a synthetic somatostatin analog used for several hormone-related conditions. Its indications are classified below by strength of evidence.

Established / FDA-approved uses

• Acromegaly: to reduce growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in patients who have not responded adequately to surgery, radiotherapy, or dopamine agonist therapy, or as an interim measure until other treatments take effect.
• Carcinoid tumors: for the symptomatic treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
• VIPomas: for symptomatic treatment of profuse watery diarrhea associated with VIP-secreting (vasoactive intestinal peptide-secreting) tumors.

Guideline-supported / adjunct uses

• Acute variceal bleeding: as an adjunct to endoscopic therapy in the management of bleeding esophageal varices, used to reduce splanchnic blood flow and portal pressure until definitive treatment is performed.
• Neuroendocrine tumors (e.g., gastroenteropancreatic NETs): as part of symptom control and, in radiolabeled form, as a diagnostic/therapeutic tool in specialist oncology settings.

Off-label / specialist uses

• Severe or refractory diarrhea in other settings (e.g., chemotherapy-induced, AIDS-related, dumping syndrome, short bowel syndrome), congenital hyperinsulinism, and certain pancreatic/gastrointestinal fistulas — used under specialist supervision as these are not primary FDA-approved indications.

Use of Octreotide Acetate for any indication should be directed and monitored by a physician experienced in the relevant condition.

Dosing of Octreotide Acetate is individualized by indication and formulation (short-acting injection vs. long-acting depot) and must be titrated by a physician based on response and tolerability.

Once a patient is stabilized and tolerates the short-acting injection, many patients with acromegaly, carcinoid syndrome, or VIPoma are transitioned to the long-acting depot formulation, given as a deep intramuscular (gluteal) injection once every 4 weeks, at doses individualized based on prior response to the short-acting form (commonly starting at 20 mg every 4 weeks). Doses above approximately 300 mcg/day of the short-acting form rarely provide additional benefit for hormone secretion control. Missed doses should not be doubled; contact the prescriber for guidance. Do not adjust the dose or stop treatment without consulting the physician.

Side effects of Octreotide Acetate are generally dose-related and often diminish with continued use. Common and important effects include:

• Gastrointestinal: diarrhea, loose stools, abdominal pain/discomfort, nausea, vomiting, constipation, and flatulence (among the most frequently reported effects).
• Gallbladder/biliary: gallstone (cholelithiasis) formation or biliary sludge with long-term use (see Precautions and Warnings).
• Glucose metabolism: hyperglycemia or hypoglycemia (see Precautions and Warnings).
• Cardiac: bradycardia, conduction abnormalities, and rarely arrhythmias (see Precautions and Warnings).
• Endocrine: hypothyroidism or subclinical thyroid function changes with long-term use.
• Local reactions: pain, stinging, or swelling at the injection site.
• Other: headache, dizziness, fatigue, and rarely hypersensitivity/anaphylactoid reactions.

Contact your physician promptly if you experience severe abdominal pain, signs of gallbladder problems (e.g., right upper abdominal pain, jaundice), unusual heart rhythm, or signs of severe allergic reaction while using Octreotide Acetate.